The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients
Paul Reilly(Boehringer Ingelheim (United States)), Lars Wallentin(Uppsala University), Michael D. Ezekowitz(Lankenau Institute for Medical Research), Sebastian Haertter(Boehringer Ingelheim (Germany)), Gerhard Nehmiz(Boehringer Ingelheim (Germany)), Thorsten Lehr(Saarland University), John W. Eikelboom(Population Health Research Institute), Susan Wang(Boehringer Ingelheim (United States)), Stuart J. Connolly(Population Health Research Institute), Salim Yusuf(Population Health Research Institute)
Cited by 826
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
|Stroke|2014|5.2k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k